Search results for " lip"

showing 10 items of 1180 documents

Betanin inhibits the myeloperoxidase/nitrite-induced oxidation of human low-density lipoproteins

2007

Production of nitrogen dioxide by the activity of myeloperoxidase (MPO) in the presence of nitrite is now considered a key step in the pathophysiology of low-density lipoprotein (LDL) oxidation. This study shows that betanin, a phytochemical of the betalain class, inhibits the production of lipid hydroperoxides in human LDL submitted to a MPO/nitrite-induced oxidation. Kinetic measurements including time-course of particle oxidation and betanin consumption, either in the presence or in the absence of nitrite, suggest that the antioxidant effect is possibly the result of various actions. Betanin scavenges the initiator radical nitrogen dioxide and can also act as a lipoperoxyl radical-scaven…

Antioxidantmedicine.medical_treatmentNitrogen DioxideBiochemistrychemistry.chemical_compoundIn vivoBetalainmedicineHumansNitriteNitritesBetaninPeroxidasebiologyBetanin myeloperoxidase nitrite low-density lipoproteins atherosclerosisGeneral MedicineFree Radical ScavengersBioavailabilityLipoproteins LDLchemistryBiochemistryMyeloperoxidasebiology.proteinBetacyaninsOxidation-ReductionLipoprotein
researchProduct

Antibacterial PEGylated Solid Lipid Microparticles for Cosmeceutical Purpose: Formulation, Characterization, and Efficacy Evaluation

2020

The development of efficacious means of delivering antioxidant polyphenols from natural sources for the treatment of skin diseases is of great interest for many cosmetic and pharmaceutical companies. Resveratrol (RSV) and Limonene (LIM) have been shown to possess good anti-inflammatory and antibacterial properties against Staphylococcus aureus infections responsible for many skin disorders, such as acne vulgaris. In this study, solid lipid microparticles are designed as composite vehicles capable of encapsulating a high amount of trans-RSV and enhancing its absorption through the stratum corneum. A microparticulate system based on mixture of PEGylate lipids, long-chain alcohols and LIM is a…

Antioxidanttape-strippingmedicine.medical_treatment02 engineering and technologyResveratrolLabrasolSettore BIO/19 - Microbiologia Generale01 natural scienceslcsh:Technologyporcine earchemistry.chemical_compoundlipid microsphereGeneral Materials ScienceAcnemedia_commonlcsh:QC120-168.851-Hexadecanol021001 nanoscience & nanotechnologyAntimicrobialmedicine.anatomical_structure0210 nano-technologyCosmeceuticallcsh:TK1-9971Drugmedia_common.quotation_subjectAbsorption (skin)Staphylococcus aureus ATCC 25923Articlelipid microspheresmedicineStratum corneumlcsh:Microscopyantimicrobial activityporcine earslcsh:QH201-278.5010405 organic chemistrylcsh:Tmedicine.diseaseCombinatorial chemistry0104 chemical scienceschemistry<i>Staphylococcus aureus</i> ATCC 25923lcsh:TA1-2040Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoResveratrolsolid lipid microparticlelcsh:Descriptive and experimental mechanicssolid lipid microparticleslcsh:Electrical engineering. Electronics. Nuclear engineeringlcsh:Engineering (General). Civil engineering (General)LimoneneMaterials
researchProduct

Accumulation of ApoE-containing triglyceride-rich lipoproteins in normolipidemic men with premature coronary artery disease

2000

ApoE triglycerides lipoproteins coronary artery disease
researchProduct

The apolipoprotein(a) moiety of lipoprotein(a) interacts with the complement activation fragment iC3b but does not functionally affect C3 activation …

1992

A previous study has shown that complement component C3 binds to recombinant apolipoprotein(a) (r-apo(a)). In the present report we have investigated the interactions between lipoprotein(a) (Lp(a)), r-apo(a) and C3 in relation to complement activation and degradation. Neither Lp(a) nor r-apo(a) affected complement activation as indicated by sheep and rabbit red blood cell hemolytic assays, and by assessment of the amount of C3a generated in zymosan-activated human serum in the presence or absence of Lp(a). Crossed immunoelectrophoretic analyses indicated that Lp(a) retarded the migration of iC3b in complement-activated serum but had no effects on C3, C3b, C3c or C3dg. Recombinant apo(a) exh…

Apolipoprotein BLipoproteinsApoprotein(a)chemistry.chemical_compoundHumansComplement ActivationbiologyComplement C3Lipoprotein(a)N-Acetylneuraminic AcidComplement systemSialic acidApolipoproteinsBiochemistrychemistryLow-density lipoproteinComplement C3bSialic Acidsbiology.proteiniC3bElectrophoresis Polyacrylamide Gellipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineImmunoelectrophoresis Two-DimensionalN-Acetylneuraminic acidLipoprotein(a)LipoproteinAtherosclerosis
researchProduct

ETC-1002: A future option for lipid disorders?

2014

ETC-1002 is a new investigational low density lipoprotein cholesterol (LDL-C)-lowering agent (Esperion Therapeutics, Inc.). ETC-1002 is a dicarboxylic acid derivative with a novel mechanism of action targeting two hepatic enzymes - adenosine triphosphate-citrate lyase (ACL) and adenosine monophosphate-activated protein kinase (AMPK), inhibiting sterol and fatty acid synthesis and promoting mitochondrial long-chain fatty acid oxidation. This agent is currently in phase II clinical research. Available data report that ETC-1002 significantly decreased LDL-C levels (up to 32%) in both patients with normal and elevated baseline levels of triglycerides. Such beneficial effect is superior to curre…

Apolipoprotein BLow density lipoprotein cholesterolBlood PressureAMP-Activated Protein Kinaseschemistry.chemical_compoundMiceMulticenter Studies as TopicDicarboxylic AcidsBeta oxidationHypolipidemic AgentsRandomized Controlled Trials as TopicHypolipidemic AgentbiologyFatty AcidsHyperlipidemiaTolerabilityLiverlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAMP-Activated Protein Kinasemedicine.drugHumanmedicine.medical_specialtyStatinmedicine.drug_classHypercholesterolemiaHyperlipidemiasClinical Trials Phase II as TopicInternal medicinemedicineAnimalsHumansFatty acid synthesisApolipoproteins BAnimalBody WeightDicarboxylic AcidAMPKCholesterol LDLAdenosineSterolCardiometabolic riskRatsETC-1002Disease Models AnimalEndocrinologychemistrybiology.proteinATP Citrate (pro-S)-LyaseRatFatty AcidLipid lowering therapy
researchProduct

Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

2020

Background Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the treatment of hypercholesterolemia. Our objective was to estimate its average effect on plasma lipids in humans and its safety profile. Methods and findings We carried out a systematic review and meta-analysis of phase II and III randomized controlled trials on bempedoic acid (PROSPERO: CRD42019129687). PubMed (Medline), Scopus, Google Scholar, and Web of Science databases were searched, with no language restriction, from inception to 5 August 2019. We included 10 RCTs (n = 3,788) comprising 26 arms (active arm [n = 2,460]; control arm [n = 1,328]). Effect sizes for changes in lipids and high-…

Apolipoprotein BPublication Ethics030204 cardiovascular system & hematologyCardiovascularGastroenterologyLipoprotein particleMedical and Health SciencesBiochemistrychemistry.chemical_compoundDatabase and Informatics Methods0302 clinical medicineMathematical and Statistical TechniquesAnticholesteremic Agents Apolipoproteins B Cholesterol Cholesterol LDL Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Dicarboxylic Acids Fatty Acids Humans Hypercholesterolemia Peptide Fragments Randomized Controlled Trials as TopicLipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert PanelMedicine and Health SciencesDicarboxylic Acids030212 general & internal medicineDatabase SearchingResearch IntegrityRandomized Controlled Trials as Topicmedicine.diagnostic_testbiologyAnticholesteremic AgentsStatisticsFatty AcidsRDrugsGeneral MedicineMetaanalysisSerious Mental IllnessLipidsPhase III as TopicMental HealthCholesterolPhysical SciencesMedicineResearch Articlemedicine.medical_specialtyRMScience PolicyLipoproteinsHypercholesterolemiaBempedoic acid hypercholesterolemia lipid profile hsCRPResearch and Analysis MethodsLDL03 medical and health sciencesClinical Trials Phase II as TopicInternal medicineGeneral & Internal MedicinemedicineHumansClinical TrialsStatistical MethodsApolipoproteins BPharmacologyPlasma Proteinsbusiness.industryCholesterolPhase II as TopicStatinsBiology and Life SciencesProteinsOdds ratioCholesterol LDLConfidence intervalPeptide FragmentschemistryClinical Trials Phase III as Topicbiology.proteinUric acidCreatine kinaseLipid profilebusinessDigestive DiseasesMathematicsPLoS Medicine
researchProduct

Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives

2020

Several lines of evidence now attest that lipoprotein[a] (Lp[a]) is a significant risk factor for many cardiovascular disorders. This enigmatic lipoprotein, composed of a single copy of apolipoprotein B (apoB) and apolipoprotein[a] (apo [a]), expresses peculiar metabolism, virtually independent from lifestyle interventions. Several therapeutic options have hence been proposed for lowering elevated Lp[a] values, with or without concomitant effect on low density lipoprotein (LDL) particles, mostly encompassing statins, ezetimibe, nicotinic acid, lipoprotein apheresis, and anti-PCSK9 monoclonal antibodies. Since all these medical treatments have some technical and clinical drawbacks, a novel s…

Apolipoprotein Bmedicine.drug_classgovernment.form_of_governmentAntisense therapyHyperlipidemias030204 cardiovascular system & hematologyPharmacologyAntisense therapy; Apolipoprotein[a]; Cardiovascular disease; Lipoprotein[a]Monoclonal antibody03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeLipoprotein[a]Internal MedicinemedicineHumans030212 general & internal medicineAntisense therapybiologybusiness.industryLipoprotein(a)Cardiovascular diseaseLipoproteins LDLchemistryConcomitantLow-density lipoproteinBlood Component Removalbiology.proteingovernmentlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessApolipoprotein[a]Lipoprotein(a)Lipoproteinmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease.

2005

Triglycerides (TGs) are vehicled by multiple particles with different abilities to promote atherosclerosis. Among plasma TG-rich lipoproteins (TRLs), subspecies may or may not contain apolipoprotein E (apoE) molecules: in this study, we evaluated the relative contribution of apoE-rich and apoE-poor TRLs to coronary atherosclerosis. We selected a group of males with premature coronary artery disease (CAD) without any of the classical nonlipid risk factors and/or high plasma lipid levels and evaluated the plasma concentration of TRL subspecies in comparison with healthy controls. Patients with CAD and controls had total cholesterol and TG levels within the normal range (despite slightly, even…

Apolipoprotein EAdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismCoronary Artery DiseaseChromatography AffinityApolipoproteins ECoronary artery diseasechemistry.chemical_compoundEndocrinologyApolipoproteins EInternal medicinemedicineHumansInsulinCoronary atherosclerosisTriglyceridesbiologyTriglycerideCholesterolCholesterol HDLLipoprotein(a)Cholesterol LDLMiddle Agedmedicine.diseaseEndocrinologyapoE triglyceride-rich lipoproteins coronary artery diseaseLogistic ModelschemistryMultivariate Analysisbiology.proteinlipids (amino acids peptides and proteins)Electrophoresis Polyacrylamide GelLipoproteinLipoprotein(a)Metabolism: clinical and experimental
researchProduct

Association of plasma markers of cholesterol homeostasis with metabolic syndrome components. A cross-sectional study.

2011

Abstract Background and aims Increased plasma phytosterols, which reflect enhanced cholesterol absorption, have been related to an increased risk of cardiovascular disease (CVD). However, high CVD risk conditions, such as obesity, diabetes and the metabolic syndrome (MetS) have been associated with reduced cholesterol absorption. We investigated associations between plasma noncholesterol sterols and MetS components. Methods and results With a cross-sectional design, we related MetS components to plasma noncholesterol sterol-to-cholesterol ratios measured by gas chromatography in 674 dyslipidemic patients and 361 healthy subjects participating in a prospective cohort study. Plasma phytostero…

Apolipoprotein EAdultMalemedicine.medical_specialtyGenotypeEndocrinology Diabetes and MetabolismMedicine (miscellaneous)LathosterolBiologychemistry.chemical_compoundHigh-density lipoproteinApolipoproteins ERisk FactorsInternal medicineDiabetes mellitusmedicineHomeostasisHumansProspective StudiesProspective cohort studyMetabolic SyndromeNutrition and DieteticsPhytosterolsOdds ratioMiddle Agedmedicine.diseaseLipid MetabolismSitosterolsEuropean Prospective Investigation into Cancer and NutritionEndocrinologyCholesterolCross-Sectional StudiesPhenotypechemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleMetabolic syndromeCardiology and Cardiovascular MedicineBiomarkersNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Low and very low density lipoprotein composition and resistance to copper-induced oxidation are not notably modified in smokers.

1997

To study whether tobacco use was associated with oxidative phenomena affecting lipoproteins, we estimated susceptibility of LDL and VLDL to an in vitro copper-mediated oxidation, and measured serum autoantibody titers against oxidized LDL in 45 middle-age healthy nonsmokers, 35 smokers and 37 ex-smokers of both sexes, taking into account the detailed lipid composition of the lipoproteins. VLDL from female smokers had higher triglyceride, phospholipid, apolipoprotein E and alpha-tocopherol content and showed a higher rate of copper-induced oxidation in comparison with those from nonsmokers (P < or = 0.05) whereas the relative composition of these particles in saturated, mono- or poly-unsatur…

Apolipoprotein EAdultMalemedicine.medical_specialtyVery low-density lipoproteinAdolescentmedicine.medical_treatmentClinical BiochemistryPhospholipidLipoproteins VLDLBiochemistrychemistry.chemical_compoundInternal medicinemedicineHumansVitamin ELipoprotein oxidationAgedAutoantibodieschemistry.chemical_classificationTriglycerideVitamin EBiochemistry (medical)SmokingProteinsGeneral MedicineMiddle AgedLipidsLipoproteins LDLEndocrinologychemistryBiochemistryLow-density lipoproteinlipids (amino acids peptides and proteins)FemaleOxidation-ReductionCopperPolyunsaturated fatty acidClinica chimica acta; international journal of clinical chemistry
researchProduct